Intravenous/oral ciprofloxacin versus intravenous ceftazidime in the treatment of serious gram-negative infections of the skin and skin structure
- 1 November 1989
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Medicine
- Vol. 87 (5) , S132-S135
- https://doi.org/10.1016/0002-9343(89)90042-9
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Ciprofloxacin: In Vitro, Experimental, and Clinical EvaluationClinical Infectious Diseases, 1988
- Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacinAntimicrobial Agents and Chemotherapy, 1987
- Treatment of skin, skin structure, bone, and joint infections with ceftazidimeThe American Journal of Medicine, 1985
- Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteersAntimicrobial Agents and Chemotherapy, 1984
- Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteriaAntimicrobial Agents and Chemotherapy, 1984
- Pharmacokinetics and tissue penetration of ciprofloxacinAntimicrobial Agents and Chemotherapy, 1983
- In vitro activity of ciprofloxacin (Bay o 9867)Antimicrobial Agents and Chemotherapy, 1983
- In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1983